{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:19:46Z","timestamp":1778728786545,"version":"3.51.4"},"reference-count":31,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:00:00Z","timestamp":1594684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Research on Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To examine the clinical features of systemic sclerosis (SSc) patients negative for SSc\u2010related autoantibodies (autoAbs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Serum samples were collected from 546 SSc patients. The presence of antinuclear antibody (ANA) was screened by indirect immunofluorescence (IIF) staining using HEp\u20102 cells. SSc\u2010related autoantibodies were identified by specific IIF staining, enzyme\u2010linked immunosorbent assay, or immunoprecipitation assay. Clinical features were analyzed among patients negative for ANA\/SSc\u2010related autoAbs, anticentromere Abs (ACA), anti\u2010topoisomerase I (anti\u2010topo I) Abs, and anti\u2010RNA polymerase (anti\u2010RNAP) Abs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 546 SSc patients, 26 (4.8%) were negative for ANA and 29 (5.3%) were ANA\u2010positive but negative for SSc\u2010related autoAbs. Regarding clinical features, patients negative for ANA\/SSc\u2010related autoAbs (n\u00a0=\u00a055) had a significantly shorter disease duration, higher proportion of the diffuse type, contracture of phalanges, diffuse pigmentation, higher modified Rodnan total skin thickness score (mRSS), and lower incidence of telangiectasia than those with ACA (n\u00a0=\u00a0224). On the other hand, younger disease onset, lower mRSS, and lower incidence of scleroderma renal crisis were observed in patients negative for ANA\/SSc\u2010related autoAbs than in those with anti\u2010RNAP Abs (n\u00a0=\u00a052). Although pitting scars were less common in patients negative for ANA\/SSc\u2010related autoAbs than in those with anti\u2010topo I Abs (n\u00a0=\u00a0144), their clinical features were similar.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Patients negative for ANA\/SSc\u2010related autoAbs form a clinically distinct subset among SSc patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.13908","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T08:39:33Z","timestamp":1594715973000},"page":"1219-1225","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical features of Japanese systemic sclerosis (SSc) patients negative for SSc\u2010related autoantibodies: A single\u2010center retrospective study"],"prefix":"10.1111","volume":"23","author":[{"given":"Miho","family":"Miyake","sequence":"first","affiliation":[{"name":"Department of Molecular Pathology of Skin Faculty of Medicine Institute of Medical, Pharmaceutical and Health Sciences Kanazawa University Kanazawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1617-086X","authenticated-orcid":false,"given":"Takashi","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology of Skin Faculty of Medicine Institute of Medical, Pharmaceutical and Health Sciences Kanazawa University Kanazawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Takehara","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology of Skin Faculty of Medicine Institute of Medical, Pharmaceutical and Health Sciences Kanazawa University Kanazawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5305-7770","authenticated-orcid":false,"given":"Yasuhito","family":"Hamaguchi","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology of Skin Faculty of Medicine Institute of Medical, Pharmaceutical and Health Sciences Kanazawa University Kanazawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,7,14]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.5301\/jsrd.5000249"},{"key":"e_1_2_6_3_1","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis","volume":"15","author":"LeRoy EC","year":"1988","journal-title":"J Rheumatol"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(08)60641-0"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.77.3.1627"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)86738-8"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116343"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-10-199311150-00007"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)38718-5"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780331210"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24586"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.139.8.2579"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39755"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370111"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.1.39"},{"key":"e_1_2_6_16_1","first-page":"751","article-title":"Progressive scleroderma and dermatomyositis","volume":"83","author":"Ricken D","year":"1977","journal-title":"Verh Dtsch Ges Inn Med"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110295"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22163"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(83)90041-7"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/2397198318783930"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2005.03.005"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2014.11.006"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27549"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230510"},{"key":"e_1_2_6_25_1","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy EC","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38098"},{"key":"e_1_2_6_27_1","first-page":"1281","article-title":"Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis","volume":"22","author":"Clements P","year":"1995","journal-title":"J Rheumatol"},{"issue":"2","key":"e_1_2_6_28_1","first-page":"S12","article-title":"Anti\u2010PM\u2010Scl antibody in patients with systemic sclerosis","volume":"30","author":"Koschik RW","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2013.844296"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08392.x"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000111"},{"key":"e_1_2_6_32_1","first-page":"S127","article-title":"(2014) Prevalence and clinical profiles of 'autoantibody\u2010negative' systemic sclerosis subjects","volume":"32","author":"Hudson M","year":"2014","journal-title":"Clin Exp Rheumatol"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.13908","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.13908","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1756-185X.13908","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.13908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T06:00:58Z","timestamp":1692252058000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.13908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,14]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1111\/1756-185X.13908"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.13908","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,14]]},"assertion":[{"value":"2020-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}